{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:20:55Z","timestamp":1791228055745,"version":"4.1.0"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pimobendan is a positive inotrope and vasodilator that may be useful in the treatment of pulmonary hypertension (PHT) secondary to degenerative mitral valve disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Hypothesis<\/jats:title>\n                    <jats:p>Pimobendan decreases the severity of PHT measured echocardiographically and improves quality-of-life scores. Changes in N-terminal probrain natriuretic peptide (NT-proBNP) concentrations will reflect improvement in severity of PHT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Ten client-owned dogs with peak tricuspid regurgitant flow velocity (TRFV) \u22653.5\u2003m\/s.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Prospective short-term, double-blinded, crossover design, with a long-term, open-label component. Short term, dogs were randomly allocated to receive either placebo or pimobendan (0.18\u20130.3\u2003mg\/kg PO q12\u2003h) for 14 days. After a 1-week washout, they received the alternative treatment for 14 days, followed by pimobendan open-label for 8 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Short-term comparison: peak TRFV decreased in all dogs on pimobendan compared with placebo from a median of 4.40 (range, 3.2\u20135.6) to 3.75 (range, 2.4\u20134.8)\u2003m\/s (P &amp;lt; .0001). NT-proBNP concentration decreased after treatment with pimobendan from a median of 2,143 (range, 450\u20133,981) to 1,329 (range, 123\u20132,411)\u2003pmol\/L (P= .0009). All dogs improved their quality-of-life score (P= .006). In the long-term comparisons, peak TRFV decreased in all dogs from a median of 4.28 (range, 3.5\u20135.7) to 3.52 (range, 2.4\u20135.0)\u2003m\/s (P &amp;lt; .0001). No significant changes in NT-proBNP or quality-of-life scores were detected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Clinical Importance<\/jats:title>\n                    <jats:p>Pimobendan lowered severity of measurable PHT, improved quality-of-life scores, and decreased NT-proBNP concentrations short-term. Long term, only the reduction in TRFV was maintained.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1939-1676.2009.0390.x","type":"journal-article","created":{"date-parts":[[2009,9,22]],"date-time":"2009-09-22T12:05:00Z","timestamp":1253621100000},"page":"1190-1196","source":"Crossref","is-referenced-by-count":47,"title":["Evaluation of Pimobendan and N-Terminal Probrain Natriuretic Peptide in the Treatment of Pulmonary Hypertension Secondary to Degenerative Mitral Valve Disease in Dogs"],"prefix":"10.1093","volume":"23","author":[{"given":"K.J.","family":"Atkinson","sequence":"first","affiliation":[{"name":"College of Veterinary Medicine, University of Missouri Departments of Veterinary Medicine and Surgery, , Columbia, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.M.","family":"Fine","sequence":"additional","affiliation":[{"name":"College of Veterinary Medicine, University of Missouri Departments of Veterinary Medicine and Surgery, , Columbia, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.A.","family":"Thombs","sequence":"additional","affiliation":[{"name":"University of Missouri Department of Statistics, , Columbia, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.J.","family":"Gorelick","sequence":"additional","affiliation":[{"name":"University of Missouri Department of Statistics, , Columbia, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.E.","family":"Durham","sequence":"additional","affiliation":[{"name":"College of Veterinary Medicine, University of Missouri Departments of Veterinary Medicine and Surgery, , Columbia, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,11,1]]},"reference":[{"key":"2026020303124727300_b1","first-page":"440","article-title":"Clinical characteristics of 53 dogs with Doppler-derived evidence of pulmonary hypertension","volume":"13","author":"Johnson","year":"1999","journal-title":"1992\u20131996"},{"key":"2026020303124727300_b2","first-page":"1772","article-title":"Doppler echocardiography-derived evidence of pulmonary arterial hypertension in dogs with degenerative mitral valve disease","volume":"229","author":"Serres","year":"2006","journal-title":"86 cases (2001\u20132005)"},{"key":"2026020303124727300_b3","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S1096-2867(99)80016-4","article-title":"Diagnosis of pulmonary hypertension","volume":"14","author":"Johnson","year":"1999","journal-title":"Clin Tech Small Anim Pract"},{"key":"2026020303124727300_b4","first-page":"498","article-title":"Textbook of Respiratory Disease in Dogs and Cats","author":"Steele","year":"2004"},{"key":"2026020303124727300_b5","first-page":"1925","article-title":"Pulmonary hypertension","volume":"162","author":"Chatterjee","year":"2002","journal-title":"Hemodynamic diagnosis and management"},{"key":"2026020303124727300_b6","first-page":"1284","article-title":"Textbook of Veterinary Internal Medicine","author":"MacDonald","year":"2005","edition":"6th ed"},{"key":"2026020303124727300_b7","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0146-2806(04)00149-5","article-title":"Pulmonary hypertension","volume":"29","author":"McLaughlin","year":"2004","journal-title":"Curr Probl Cardiol"},{"key":"2026020303124727300_b8","first-page":"887","article-title":"Kirk's Current Veterinary Therapy XII","author":"Johnson","year":"1995"},{"key":"2026020303124727300_b9","first-page":"99","article-title":"Pulmonary hypertension and cardiovascular sequelae in 54 Dogs","volume":"2","author":"Pyle","year":"2004","journal-title":"Intern J Appl Res Vet Med"},{"key":"2026020303124727300_b10","first-page":"179","article-title":"Manual of Veterinary Echocardiography","author":"Boon","year":"1998"},{"key":"2026020303124727300_b11","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.cvsm.2004.05.005","article-title":"Neuroendocrine evaluation of cardiac disease","volume":"34","author":"Sisson","year":"2004","journal-title":"Vet Clin North Am"},{"key":"2026020303124727300_b12","first-page":"R158","article-title":"Atrial BNP endocrine function during chronic unloading of the normal canine heart","volume":"288","author":"Lisy","year":"2005","journal-title":"Am J Physiol"},{"key":"2026020303124727300_b13","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1590\/S0004-27302006000200006","article-title":"The broad homeostatic role of natriuretic peptides","volume":"50","author":"Maack","year":"2006","journal-title":"Arquivos brasileiros de endocrinologia e metabologia"},{"key":"2026020303124727300_b14","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.amjcard.2006.02.061","article-title":"N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension","volume":"98","author":"Andreassen","year":"2006","journal-title":"Am J Cardiol"},{"key":"2026020303124727300_b15","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1378\/chest.06-1758","article-title":"N-terminal pro-brain natriuretic peptide and renal insufficiency as predictors of mortality in pulmonary hypertension","volume":"131","author":"Leuchte","year":"2007","journal-title":"Chest"},{"key":"2026020303124727300_b16","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1748-5827.2007.00510.x","article-title":"The diagnostic accuracy of different natriuretic peptides in the investigation of canine cardiac disease","volume":"49","author":"Boswood","year":"2007","journal-title":"J Small Anim Pract"},{"key":"2026020303124727300_b17","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.2460\/javma.232.11.1674","article-title":"Evaluation of circulating amino terminal-pro-B-type natriuretic peptide concentration in dogs with respiratory distress attributable to congestive heart failure or primary pulmonary disease","volume":"232","author":"Fine","year":"2008","journal-title":"J Am Vet Med Assoc"},{"key":"2026020303124727300_b18","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.2460\/javma.232.10.1496","article-title":"Clinical utility of serum N-terminal pro-B-type natriuretic peptide concentration for identifying cardiac disease in dogs and assessing disease severity","volume":"232","author":"Oyama","year":"2008","journal-title":"J Am Vet Med Assoc"},{"key":"2026020303124727300_b19","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/BF00789302","article-title":"Comparison of the effects of levosimendan, pimobendan, and milrinone on canine left ventricular-arterial coupling and mechanical efficiency","volume":"91","author":"Pagel","year":"1996","journal-title":"Basic Res Cardiol"},{"key":"2026020303124727300_b20","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1476-5381.1996.tb15716.x","article-title":"Influence of levosimendan, pimobendan, and milrinone on the regional distribution of cardiac output in anaesthetized dogs","volume":"119","author":"Pagel","year":"1996","journal-title":"Br J Pharmacol"},{"key":"2026020303124727300_b21","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0022-3565(24)36774-6","article-title":"The cardiac effects of pimobendan (but not amrinone) are preserved at rest and during exercise in conscious dogs with pacing-induced heart failure","volume":"282","author":"Ohte","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"2026020303124727300_b22","first-page":"S1","article-title":"Hemodynamic profile of the cardiotonic agent pimobendan","volume":"14","author":"Van Meel","year":"1989","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026020303124727300_b23","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1023\/A:1027328614686","article-title":"Low-dose systemic phosphodiesterase III inhibitor pimobendan combined with prostacyclin therapy in a patient with severe primary pulmonary hypertension","volume":"17","author":"Watanabe","year":"2003","journal-title":"Cardiovasc Drugs Ther"},{"key":"2026020303124727300_b24","first-page":"79","article-title":"Effects of low dose pimobendan in patients with cor-pulmonale","volume":"34","author":"Nakatani","year":"1999","journal-title":"J Cardiol"},{"key":"2026020303124727300_b25","first-page":"847","article-title":"Effects of pimobendan on pulmonary hypertension in patients with chronic pulmonary emphysema","volume":"35","author":"Yamazaki","year":"1997","journal-title":"Nihon Kyobu Shikkan Gakkai Zasshi"},{"key":"2026020303124727300_b26","first-page":"259","article-title":"Beta-blocker therapy combined with low-dose pimobendan in patients with idiopathic dilated cardiomyopathy and chronic obstructive pulmonary disease","volume":"16","author":"Shiga","year":"2002","journal-title":"Report on two cases"},{"key":"2026020303124727300_b27","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10557-006-0498-3","article-title":"New insights in the treatment strategy for pulmonary arterial hypertension","volume":"20","author":"Sahara","year":"2006","journal-title":"Cardiovasc Drugs Ther"},{"key":"2026020303124727300_b28","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/j.1939-1676.2006.tb00711.x","article-title":"Retrospective evaluation of sildenafil citrate as a therapy for pulmonary hypertension in dogs","volume":"20","author":"Bach","year":"2006","journal-title":"J Vet Intern Med"},{"key":"2026020303124727300_b29","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1111\/j.1939-1676.2007.tb01947.x","article-title":"Sildenafil citrate therapy in 22 dogs with pulmonary hypertension","volume":"21","author":"Kellum","year":"2007","journal-title":"J Vet Intern Med"},{"key":"2026020303124727300_b30","first-page":"189","article-title":"Veterinary Emergency and Critical Care Manual","author":"O'Sullivan","year":"2006"},{"key":"2026020303124727300_b31","first-page":"S81","article-title":"Effect of azotemia on serum N-terminal proBNP concentration in dogs with normal cardiac function","volume":"11","author":"Schmidt","year":"2009","journal-title":"A pilot study"},{"key":"2026020303124727300_b32","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1740-8261.1994.tb01588.x","article-title":"Recommendations for standards in tranthoracic two-dimensional echocardiography in the dog and cat","volume":"35","author":"Thomas","year":"1994","journal-title":"Vet Radiol Ultrasound"},{"key":"2026020303124727300_b33","first-page":"1280","article-title":"Diagnostic value of echo-Doppler and tissue Doppler imaging in dogs with pulmonary arterial hypertension","volume":"21","author":"Serres","year":"2007","journal-title":"J Vet Intern Med"},{"key":"2026020303124727300_b34","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/j.1939-1676.2006.tb01805.x","article-title":"Doppler echocardiographic prediction of pulmonary hypertension in West Highland White Terriers with chronic pulmonary disease","volume":"20","author":"Schober","year":"2006","journal-title":"J Vet Intern Med"},{"key":"2026020303124727300_b35","article-title":"Essentials of Canine and Feline Electrocardiography","author":"Tilley","year":"1992","edition":"3rd ed"},{"key":"2026020303124727300_b36","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2460\/javma.1995.206.02.194","article-title":"Vertebral scale system to measure canine heart size in radiographs","volume":"206","author":"Buchanan","year":"1995","journal-title":"J Am Vet Med Assoc"},{"key":"2026020303124727300_b37","doi-asserted-by":"crossref","first-page":"249","DOI":"10.5326\/0420249","article-title":"Clinical efficacy of pimobendan versus benazepril for the treatment of acquired atrioventricular valvular disease in dogs","volume":"42","author":"Lombard","year":"2006","journal-title":"J Am Anim Hosp Assoc"},{"key":"2026020303124727300_b38","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.2460\/javma.2005.226.1864","article-title":"Development and evaluation of a questionnaire for assessing health-related quality of life in dogs with cardiac disease","volume":"226","author":"Freeman","year":"2005","journal-title":"J Am Vet Med Assoc"},{"key":"2026020303124727300_b39","first-page":"1124","article-title":"Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease","volume":"22","author":"H\u00e4ggstr\u00f6m","year":"2008","journal-title":"The QUEST study"},{"key":"2026020303124727300_b40","first-page":"113","article-title":"Doppler Ultrasound in Cardiology: Physical Principles and Clinical Application","author":"Hatle","year":"1982"},{"key":"2026020303124727300_b41","first-page":"29","article-title":"Pulmonary hypertension and left heart disease","volume":"62","author":"O'Callaghan","year":"2008","journal-title":"Emerging concepts and treatment strategies"},{"key":"2026020303124727300_b42","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.tvjl.2007.12.026","article-title":"Predictive value of natriuretic peptides in dogs with mitral valve disease","volume":"180","author":"Tarnow","year":"2009","journal-title":"Vet J"},{"key":"2026020303124727300_b43","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1183\/09031936.00016006","article-title":"NT-proBNP reflects right ventricular structure and function in pulmonary hypertension","volume":"28","author":"Gan","year":"2006","journal-title":"Eur Respir J"},{"key":"2026020303124727300_b44","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1016\/j.jvc.2009.03.003","article-title":"Weekly variability of plasma and serum NT-proBNP measurements in normal dogs","volume":"11","author":"Kellihan","year":"2009","journal-title":"J Vet Cardiol"},{"key":"2026020303124727300_b45","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.cardfail.2006.09.003","article-title":"The biologic variation of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in stable heart failure patients","volume":"13","author":"O'Hanlon","year":"2007","journal-title":"J Card Fail"},{"key":"2026020303124727300_b46","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1939-1676.2007.0008.x","article-title":"Survival characteristics and prognostic variables of dogs with mitral regurgitation attributable to myxomatous valve disease","volume":"22","author":"Borgarelli","year":"2008","journal-title":"J Vet Intern Med"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1939-1676.2009.0390.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/23\/6\/1190\/66653773\/j.1939-1676.2009.0390.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/23\/6\/1190\/66653773\/j.1939-1676.2009.0390.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T08:12:59Z","timestamp":1770106379000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/23\/6\/1190\/8447169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,1]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,11,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1939-1676.2009.0390.x","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2009,11]]},"published":{"date-parts":[[2009,11,1]]}}}